Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2020; 10(10): 23-29


In silico targeting methylerythritol phosphate pathway IspD enzyme of Mycobacterium tuberculosis for novel anti-mycobacterial drug discovery

Pratik Kumar, Maneesh Kumar, Harish Kumar, Sindhuprava Rana, Jainendra Kumar, Ganesh Chandra Sahoo.




Abstract
Cited by 0 Articles

The incidence of drug-resistant tuberculosis (TB) is the biggest challenge for the global TB control. Currently, resistance has been detected for almost all key anti-TB drugs. Therefore, an approach for a novel drug discovery with new targets is urgently required. A computational study was carried out to target 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase Isopentenyl pyrophosphate (IspD), an enzyme of the methylerythritol phosphate pathway that is essential for mycobacterial survival. Molecular docking was carried out with the available ligands using Discovery studio version 3.5. Among these ligands, rosuvastatin (RST) emerged as one of the suitable compounds against the enzyme that significantly interacted at the active site of the enzyme with the highest LibDock score of 121.08. Gly16, Arg83, Thr84, and Thy190 are potential amino acid residues which contributed to the protein–ligand interaction. The significant interaction between IspD and RST suggested the potency of the ligand in curing TB.

Key words: Tuberculosis, MEP pathway, IspD, Rosuvastatin, MTBC






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.